Terms ending in 2029
Bayer Pharma Aktiengesellschaft
Every in-force patent on Bayer Pharma Aktiengesellschaft's record whose computed term ends in 2029, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,067,407 | Substituted Dihydropyrazolones and Their Use In force · High confidence | Bayer Intellectual Property GmbH | In force | High confidence | |
| US 8,389,520 | Substituted Dihydropyrazolones for Treating Cardiovascular and Hematological Diseases In force · High confidence | Bayer Intellectual Property GmbH | In force | High confidence | |
| US 8,916,600 | Phenyl and Benzodioxinyl Substituted Indazoles Derivatives In force · High confidence | Bayer Pharma Aktiengesellschaft | In force | High confidence | |
| US 8,188,270 | Novel Polymorphous Form of 5-Chloro-N-({(5S)-2-OXO-3[4-(3-OXO-4-Morpholinyl)-PHENYL]-1,3-Oxazolidine-5-YL}-METHYL)-2-Thiophene Carboxamide In force · High confidence | Bayer Pharma Aktiengesellschaft | In force | High confidence | |
| US 8,962,013 | Multi-layered transdermal system with triazine UV absorber In force · High confidence | Luye Pharma Switzerland AG | In force | High confidence | |
| US 9,035,023 | Bombesin Analog Peptide Antagonist Conjugates In force · High confidence | Bayer Pharma Aktiengesellschaft | In force | High confidence | |
| US 8,613,950 | Pharmaceutical Forms with Improved Pharmacokinetic Properties In force · High confidence | Bayer Intellectual Property GmbH | In force | High confidence | |
| US 8,334,291 | Novel Aliphatically Substituted Pyrazolopyridines, and the Use Thereof In force · High confidence | Bayer Pharma Aktiengesellschaft | In force | High confidence | |
| US 9,359,362 | Triazolo and Tetrazolo Pyrimidine Derivatives as Hne Inhibitors for Treating Copd In force · Medium confidence | PH Pharma Co., Ltd. | In force | Medium confidence |
9 of 9 patents shown. Soonest term end first, then patent number.
4 of these are in force and held by Bayer Pharma Aktiengesellschaft.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.